Atrial fibrillation is a common heart condition that affects how the heart beats.

Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the ...

The advertiser paid a fee to promote this sponsored video and may have influenced or authored the content. The views expressed in this video are those of the advertiser and do not necessarily reflect ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

{} {} Atrial Fibrillation affects more than 2.5 million Americans.{}Many of them live with the heart condition, but it can lead to life-threatening problems. Doctors at Baptist Hospital are{}using a ...

Previously, patients with advanced atrial fibrillation (AF/AFib) had limited treatment choices. Since February 2024, West ...

Loyola Medicine is enrolling patients in a landmark clinical trial of a new procedure to treat atrial fibrillation, the most common type of irregular heartbeat. The clinical trial will combine the ...

Abbott (ABT)'s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – ...

The Food and Drug Administration has approved Medtronic's Arctic Front device a for atrial fibrillation patients who don't respond to drug therapy. This week at St. Joseph's Hospital in Tampa, a ...

Q: Twenty years ago, after an EKG, my doctor ordered me to go to an emergency room immediately. I had atrial fibrillation, and for the next 14 years I survived daily Coumadin, monthly visits to get my ...